Leana Wen Sells 525 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) Director Leana Wen sold 525 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $167.63, for a total transaction of $88,005.75. Following the completion of the sale, the director owned 21,092 shares of the company’s stock, valued at $3,535,651.96. This trade represents a 2.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Glaukos Trading Down 0.4%

Shares of Glaukos stock opened at $170.19 on Wednesday. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $184.00. The stock has a market cap of $10.04 billion, a P/E ratio of -52.37 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The stock’s 50 day simple moving average is $140.20 and its 200-day simple moving average is $126.07.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Analysts predict that Glaukos Corporation will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Glaukos

A number of large investors have recently modified their holdings of the business. Summit Global Investments purchased a new position in Glaukos in the second quarter worth $580,000. Oppenheimer Asset Management Inc. purchased a new stake in Glaukos in the 2nd quarter valued at approximately $2,734,000. Walleye Capital LLC purchased a new stake in shares of Glaukos in the second quarter valued at $3,750,000. Handelsbanken Fonder AB boosted its stake in shares of Glaukos by 5.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 19,800 shares of the medical instruments supplier’s stock worth $2,767,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Valeo Financial Advisors LLC boosted its position in Glaukos by 4.7% during the second quarter. Valeo Financial Advisors LLC now owns 9,892 shares of the medical instruments supplier’s stock worth $1,383,000 after acquiring an additional 440 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on GKOS shares. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Friday, July 17th. UBS Group began coverage on shares of Glaukos in a report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price target for the company. Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Citigroup increased their target price on shares of Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $177.33.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.